12960 Federal Register / Vol. 60, No. 46 / Thursday, March 9, 1995 / Notices

agreement, subject to any legally

recognized privilege, and upon written

request with reasonable notice to

respondent made to their principal

offices, respondent shall permit any

duly authorized representative or

representatives of the Commission:

a. Access, during office hours of

respondent and in the presence of

counsel, to inspect and copy all books,

ledgers, accounts, correspondence,

memoranda and other records and

documents in the possession or under

the control of respondent relating to any

matters contained in this order; and

b. Upon five (5) days’ notice to

respondent and without restraint or

interference therefrom, to interview

officers or employees of respondent,

who may have counsel present,

regarding such matters.

This agreement shall not be binding

until approved by the Commission.

Exhibit A

Hold Separate Assets

1. Perl Funeral Home, 426 W. 6th Street,

Medford, OR 97501–2713

2. Perl With Siskiyou Funeral Service,

2100 Siskiyou Boulevard, Medford,

OR 97504–8048

3. Siskiyou Memorial Park (cemetery),

2100 Siskiyou Boulevard, Medford,

OR 97504–8048

4. Siskiyou Memorial Park (crematory),

2100 Siskiyou Boulevard, Medford,

OR 97504–8048

Analysis of Proposed Consent Order To

Aid Public Comment

The Federal Trade Commission

(‘‘Commission’’) has provisionally

accepted an agreement containing a

proposed consent order with Service

Corporation International (‘‘SCI’’), and

has placed the proposed consent on the

public record for sixty (60) days.

Anyone interested in the proposed order

may comment on it during this time.

After sixty (60) days, the Commission

will again review the agreement and any

comments received, and will decide

whether it should withdraw from the

agreement or make final the agreement’s

proposed consent order.

The proposed consent order stems

from SCI’s proposed acquisition of

certain assets and businesses of

Uniservice Corporation (‘‘Uniservice’’).

According to the proposed complaint,

this acquisition, if consummated, would

violate Section 7 of the Clayton Act, as

amended 15 U.S.C. 18, and Section 5 of

the FTC Act, as amended, 15 U.S.C. 45,

in the markets for funerals and

perpetual care cemetery services in

Medford, Oregon, and its immediate

environs.

The proposed consent order would

remedy this alleged violation by

requiring that SCI either divest the

Uniservice assets and businesses in this

region within one (1) year (Order

Paragraph II.A) or transfer responsibility

for divestiture to a trustee appointed by

the Commission (Order Paragraph III).

Uniservice’s crematory and trade names

are among these assets and businesses

because they may be important to a

buyer’s competitive viability in the

markets for funerals or perpetual care

cemetery services, but SCI’s obligations

with regard to them would cease if the

buyer does not wish to purchase them.

However divestiture is accomplished,

SCI could sell only to an acquirer or

acquirers approved in advance by the

Commission (Order Paragraphs II.B and

III.B.2).

Pending divestiture, the proposed

order would preserve the status quo in

two respects. First, to preserve the

properties to be divested, SCI must

maintain the viability and marketability

of the properties and protect them from

harm (Order Paragraph II.C). Second, to

preserve competition between SCI and

the properties to be divested, SCI must

hold the properties separate from SCI’s

operations (Order Paragraph II.D).

In the remainder of the order, SCI

agrees for ten (10) years to obtain prior

approval from the Commission before

acquiring any interest in funeral

establishments or cemeteries in Jackson

County, Oregon (Order Paragraph IV),

report to the Commission concerning its

efforts to divest and comply with the

prior approval requirement (Order

Paragraph V), notify the Commission of

any changes in SCI that might affect its

compliance with the order (Order

Paragraph VI), and permit Commission

representatives to review documents

and interview employees to ensure

compliance with the order (Order

Paragraph VII).

The purpose of this analysis is to

assist public comment on the proposed

order. It is not an official interpretation

of the order or the accompanying

settlement and is not intended to

modify their terms.

Donald S. Clark,

Secretary.

[FR Doc. 95–5792 Filed 3–8–95; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Tentative

Schedule of Meetings for 1995

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing a

tentative schedule of forthcoming

meetings of its public advisory

committees for 1995. At the request of

the Commissioner of Food and Drugs

(the Commissioner), the Institute of

Medicine (the IOM) conducted a study

of the use of FDA’s advisory

committees. The IOM recommended

that the agency publish an annual

tentative schedule of its meetings in the

Federal Register. In response to that

recommendation, FDA is publishing its

annual tentative schedule of meetings.

FOR FURTHER INFORMATION CONTACT:

Donna M. Combs, Committee

Management Office (HFA–306), Food

and Drug Administration, 5600 Fishers

Lane, Rockville, MD 20857, 301–443–

2765.

SUPPLEMENTARY INFORMATION: The IOM,

at the request of the Commissioner,

undertook a study of the use of FDA’s

advisory committees. In its final report,

the IOM recommended that FDA adopt

a policy of publishing an advance yearly

schedule of its upcoming public

advisory committee meetings in the

Federal Register. FDA has implemented

this recommendation. A tentative

schedule of forthcoming meetings will

be published annually in the Federal

Register. The annual publication of

tentatively scheduled advisory

committee meetings will provide both

advisory committee members and the

public with the opportunity, in advance,

to schedule attendance at FDA’s

upcoming advisory committee meetings.

The schedule is tentative and

amendments to this notice will not be

published in the Federal Register. FDA

will, however, publish a Federal

Register notice 15 days in advance of

each upcoming advisory committee

meeting, announcing the meeting (21

CFR 14.20).

The following list announces FDA’s

tentatively scheduled advisory

committee meetings for 1995:
Federal Register / Vol. 60, No. 46 / Thursday, March 9, 1995 / Notices 12961

Committee name Dates of meetings

OFFICE OF THE COMMISSIONER

Board of Tea Experts ........................................................................................ February 27–28

Science Board to the Food and Drug Administration ........................................ June 27–28

October 24–25

National Task Force on AIDS Drug Development ............................................ January 19

February 6–7 (subcommittee meeting; Drug Discovery Issues)

February 23–24

June 1–2

September 21–22

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

Allergenic Products Advisory Committee .......................................................... March 10

May 18–19

November 20–21

Biological Response Modifiers Advisory Committee ......................................... April 10–11

July 13–14

November 13–14

Blood Products Advisory Committee ................................................................. March 15

March 23–24

June 22–23

September 28–29

December 14–15

Vaccines and Related Biological Products Advisory Committee ...................... January 26–27

March 17

April 26–27

July 6–7

October 26–27

CENTER FOR DRUG EVALUATION AND RESEARCH

Anesthetic and Life Support Drugs Advisory Committee .................................. January 17–18

July 10–11

November 13–14

Anti-Infective Drugs Advisory Committee .......................................................... April 20–21

September 21–22

Antiviral Drugs Advisory Committee .................................................................. January 11–12 (joint meeting with Nonprescription Drugs Advisory Committee)

March 30–31 (subcommittee meeting; Immunosuppressive

Drugs)

April 3–4

June 12–13

October 19–20

Arthritis Advisory Committee ............................................................................. March 27–28 (joint meeting March 28, with Nonprescription

Drugs Advisory Committee)

May 25–26

September 18–19

December 4–5

Cardiovascular and Renal Drugs Advisory Committee ..................................... February 23–24

June 1–2

October 19–20

Dermatologic and Ophthalmic Drugs Advisory Committee (formerly Dermatologic Drugs Advisory Committee).

April 27–28

November 3–4

Drug Abuse Advisory Committee ...................................................................... May 2–3

August 2–3

December 4–5

Endocrinologic and Metabolic Drugs Advisory Committee ............................... January 19–20

February 23–24

Fertility and Maternal Health Drugs Advisory Committee ................................. June 29–30

Gastrointestinal Drugs Advisory Committee ...................................................... July 13–14

Generic Drugs Advisory Committee .................................................................. June 14–15

September 28–29

Medical Imaging Drugs Advisory Committee .................................................... June 22–23

Nonprescription Drugs Advisory Committee ...................................................... January 11–13 (joint meeting January 11–12 with Antiviral

Drugs Advisory Committee)

March 27–28 (joint meeting with Arthritis Advisory Committees)

July 13–14

September 28–29

November 16–17

Oncologic Drugs Advisory Committee ............................................................... February 14
12962 Federal Register / Vol. 60, No. 46 / Thursday, March 9, 1995 / Notices

Committee name Dates of meetings

June 8–9

September 18–19

December 4–5

Peripheral and Central Nervous System Drugs Advisory Committee ............... June 5–6

September 18–19

December 4–5

Psychopharmacologic Drugs Advisory Committee ............................................ February 6

April 24–25

July 17–18

October 16–17

Pulmonary-Allergy Drugs Advisory Committee ................................................. April 13–14

CENTER FOR FOOD SAFETY AND APPLIED NUTRITION

Food Advisory Committee ................................................................................. February 22 (subcommittee meeting)

May 8–9

August 14–15

November 6–7

CENTER FOR DEVICES AND RADIOLOGICAL HEALTH

Device Good Manufacturing Practice Advisory Committee .............................. June 6–7

Medical Devices Advisory Committee ...............................................................

Anesthesiology and Respiratory Therapy Devices Panel .............................. January 20

April 21

September 8

November 17

Circulatory System Devices Panel ................................................................. May 8–10

August 14–15

December 11–12

Clinical Chemistry and Clinical Toxicology Devices Panel ............................ April 6–7

July 27–28

September 25–26

Dental Products Panel ................................................................................... April 3–5 (Plaque subcommittee meeting)

April 18–20

August 8–10

August 15–17 (Plaque subcommittee meeting)

December 4–6 (Plaque subcommittee meeting)

December 5–7

Ear, Nose, and Throat Devices Panel ........................................................... April 20–21

July 20–21

October 19–20

Gastroenterology-Urology Devices Panel ...................................................... January 20

April 21

July 20–21

October 19–20

General and Plastic Surgery Devices Panel .................................................. July 18–19

General Hospital and Personal Use Devices Panel ...................................... July 17–18

Hematology and Pathology Devices Panel ................................................... June 9

September 22

Immunology Devices Panel ........................................................................... March 31

June 23

September 15

December 1

Microbiology Devices Panel ........................................................................... April 27–28

Neurological Devices Panel ........................................................................... September 14–15

Obstetrics-Gynecology Devices Panel ........................................................... April 24–25

July 20–21

October 23

Ophthalmic Devices Panel ............................................................................. January 26

July 20–21

October 19–20

Orthopedic and Rehabilitation Devices Panel ............................................... June 12

Radiological Devices Panel ........................................................................... March 6

June 19

September 11

December 11

National Mammography Quality Assurance Advisory Committee ..................... January 23–25

April 24–26

July 17–19

October 16–18

Technical Electronic Product Radiation Safety Standards Committee ............. No meetings planned

CENTER FOR VETERINARY MEDICINE

Veterinary Medicine Advisory Committee .......................................................... May 10–11

October 18–19
Federal Register / Vol. 60, No. 46 / Thursday, March 9, 1995 / Notices 12963

Committee name Dates of meetings

NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH

Advisory Committee on Special Studies Relating to the Possible Long-Term

Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee).

February 13–14

Science Board to the National Center for Toxicological Research ................... May 9

Dated: March 2, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.

[FR Doc. 95–5824 Filed 3–8–95; 8:45 am]

BILLING CODE 4160–01–F

Health Resources and Services

Administration Advisory Council;

Meeting

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), announcement is

made of the following National

Advisory bodies scheduled to meet

during the month of April 1995:

Name: Advisory Committee on Infant

Mortality.

Date & Time: April 6–7, 1995, 9:00 a.m.

Place: Embassy Row Hotel, 2015

Massachusetts Ave., NW., Washington, DC

20037.

The meeting is open to the public.

Purpose: The Committee provides advice

and recommendations to the Secretary on the

following: Department programs which are

directed at reducing infant mortality and

improving the health status of pregnant

women and infants; how best to coordinate

the variety of Federal, State, local and private

programs and efforts that are designed to deal

with the health and social problems

impacting on infant mortality; and the

implementation of the Healthy Start initiative

and infant mortality objectives from Healthy

People: 2000: National Health Promotion and

Disease Prevention Objectives.

Agenda: Topics that will be discussed

include: Presentation on Quality Assurance

in Managed Care and Medicaid Waiver

Programs; updates on the Healthy Start

Program; Welfare Reform; Prenatal Care

Issues; and swearing in of new Committee

members.

Anyone requiring information regarding

the Committee should contact Dr. Peter van

Dyck, Executive Secretary, Advisory

Committee on Infant Mortality, Health

Resources and Services Administration,

Room 18–44, Parklawn Building, 5600

Fishers Lane, Rockville, Maryland 20857,

Telephone (301) 443–2204.

Persons interested in attending any portion

of the meeting should contact Ms. Kerry P.

Nesseler, Maternal and Child Health Bureau,

Health Resources and Services

Administration, Telephone (301) 443–2204.

Name: National Commission on Allied

Health.

Date & Time: April 17–18, 1995, 8:00 a.m.

Place: Crystal Gateway Marriott, 1700

Jefferson Davis Highway, Arlington, Virginia

22202, (703) 920–3230.

The meeting is open to the public.

Purpose: The National Commission on

Allied Health shall: (1) make

recommendations to the Secretary of Health

and Human Services, the Committee on

Labor and Human Resources of the Senate,

and the Committee on Energy and Commerce

of the House of Representatives, with respect

to: (A) The supply and distribution of allied

health personnel throughout the United

States; (B) current and future shortages or

excesses of allied health personnel,

particularly in medically underserved and

rural communities; (C) priority research

needs within the allied health professions;

(D) appropriate Federal policies relating to

the matters described in subparagraphs (A)

through (C), including policies concerning

changes in the financing of undergraduate

and graduate allied health programs, changes

in the types of allied health education, and

the appropriate Federal role in the

development of a research base in the allied

health professions; (E) appropriate efforts to

be carried out by health care facilities,

schools and programs of allied health, and

professional associations with respect to the

matter referred to in subparagraph (A),

including efforts for changes in

undergraduate and graduate allied health

education programs, and private support for

research initiatives; (F) deficiencies and

needs for improvements in existing data

bases concerning the supply and distribution

of training programs for allied health in the

United States and steps that should be taken

to eliminate such deficiencies; and (G)

problems, and recommendations for the

resolution of such problems, relating to the

roles and functions of professionals within

the allied health fields and other fields such

as medicine and dentistry; and (2) encourage

entities providing allied health education to

conduct activities to voluntarily achieve the

recommendations of the Commission.

Agenda: The agenda includes review by

the Commission members of the Final Report

incorporating materials from the four

Committees (education, data, research, and

workforce) and white papers; presentation of

cross-cutting issues and final

recommendation; discussion of issues and

recommendations with professional

associations, educators, licensing boards,

third-party payers, consumer groups, and

others.

Anyone requiring information regarding

the Committee should contact Mr. Neil H.

Sampson, Executive Secretary, National

Commission on Allied Health, Bureau of

Health Professions, Health Resources and

Services Administration, room 8–101,

Parklawn Building, 5600 Fishers Lane,

Rockville, Maryland 20857, Telephone (301)

443–6853.

Name: National Advisory Council on

Migrant Health.

Date and Time: April 22–23, 1995—8:00

a.m.

Place: Doubletree Hotel, 201 Marquette,

NW., Albuquerque, NM 87102, 505/247–

3344.

The meeting is open to the public.

Purpose: The Council is charged with

advising, consulting with, and making

recommendations to the Secretary and the

Administrator, Health Resources and

Services Administration, concerning the

organization, operation, selection, and

funding of Migrant Health Centers and other

entities under grants and contracts under

section 329 of the Public Health Service Act.

Agenda: The agenda includes a overview

of Council general business activities and

priorities. In addition, the Council will

review and discuss the 1995/96 National

Advisory Council on Migrant Health

Recommendations.

The Council meeting is being held in

conjunction with the National Association of

Community Health Centers, Annual Migrant

Health Conference, April 24–27, 1995.

Anyone requiring information regarding

the subject Council should contact Susan

Hagler, Migrant Health Program, Staff

Support to the National Advisory Council on

Migrant Health, Bureau of Primary Care,

Health Resources and Services

Administration, 4350 East West Highway,

Room 7A6–1, Rockville, Maryland 20857,

Telephone (301) 594–4302.

Name: National Advisory Council on

Nurse Education and Practice.

Date and Time: April 27, 1995—8:30 a.m.

to 5:00 p.m.

Place: Woodmont Room, Crown Plaza

Hotel, 1750 Rockville Pike, Rockville,

Maryland 20852.

Date and Time: April 28, 1995—8:30 a.m.

to 3:00 p.m.

Place: Conference Room E, 3rd Floor, B

Wing, Parklawn Building, 5600 Fishers Lane,

Rockville, Maryland 20857.

The meeting is open to the Public 8:30

a.m.–5:00 p.m., April 27 and on April 28

from 8:30 a.m.–10:30 a.m. and from 1:00 p.m.

for the remainder of the meeting.

Closed April 28, 10:30 a.m.–1:00 p.m.

Purpose: The Council advises the Secretary

and Administrator, Health Resources and

Services Administration, concerning general

regulations and policy matters arising in the

administration of the Nursing Education and

Practice Improvement Amendments of 1992

(P.L. 102–148). The Council also performs

final review of selected grant applications for

Federal Assistance, and makes

recommendations to the Administrator,

HRSA.

Agenda: Agenda items for the meeting will

cover announcements, considerations of

minutes of the previous meeting, the reports

of the Administrator, Health Resources and